<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927355</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00014509</org_study_id>
    <secondary_id>08006</secondary_id>
    <nct_id>NCT00927355</nct_id>
  </id_info>
  <brief_title>Effect of Thiazolidinediones on Human Bone</brief_title>
  <official_title>Effects of Thiazolidinediones on Human Bone Marrow Stromal Cell Differentiation Capacity:In Vitro and In Vivo- A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will prospectively study 2 groups of diabetic patients treated with pioglitazone or
      placebo for 26 weeks. Bone marrow aspirates will be obtained from these patients at baseline
      and after 26 weeks of treatment, and hBMCs will be isolated from these bone marrow
      aspirations. The ability of hBMCs to differentiate into osteoblast and adipocytes lineages
      will be compared before and after treatment with pioglitazone and compared to placebo. In
      parallel, clinical markers of bone formation and resorption as well as bone mineral density
      will be assessed before and after 26 weeks of treatment. Primary endpoint for this study will
      be detection of change in number of osteoblasts or adipocytes from cultured hBMCs between
      study groups and within each group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      E2a. Screening: Prescreening of electronic medical records will be used as much as possible
      to reduce screen failure rates. Patients will undergo a full history (with special focus on
      inclusion and exclusion criteria), physical exam, and blood draw. Lab work will consist of
      CBC, PT, PTT, CMP, HbA1c, PTH, serum beta-HCG in females of childbearing potential and
      testosterone in males. We will measure 25(OH) Vitamin D at baseline and completion of the
      study.

      E2b. Study visits Subjects will be admitted to the Grady GCRC after an overnight fast at the
      initial visit and at 26 weeks. Study drug will be dispensed at the initial visit. At the
      initial visit and at 26 weeks, subjects will undergo bone marrow aspiration by a skilled and
      certified Hematology Oncology fellow, bone densitometry (DXA) of their hip and spine, and a
      blood.draw (5mls).

      Subjects will be seen in follow-up at the Grady GCRC at 2 weeks and every 4 weeks thereafter
      for measurement of body weight, vital signs, and targeted history looking for any side
      effects from study drugs.

      Study drug will be dispensed to patients at baseline and on monthly follow-up visits
      thereafter. To assess compliance, subjects will be instructed to return any unused drug, and
      if the subject takes less than 75% of the study medication, the patient will be withdrawn
      from the study. Patients will be monitored closely for development of side effects. Glycemic
      control will be assessed with HbA1c measurements at baseline, 12 weeks into the study and at
      end of study. Home blood sugars, fasting and occasional postprandial blood sugars will be
      assessed at each of the study visits.

      E2b.2. Bone Marrow Biopsy aspiration: Bone marrow (BM) aspiration will be done by a
      hematology and oncology fellow, Dr. Simbo Aduloju, who is certified in doing these procedures
      at the Grady GCRC. Subjects will be pre-medicated 30 minutes prior to the procedure with oral
      Lorazepam 2mg and Tylenol 500mg for analgesia.The only absolute contraindication to BM
      aspirations is the presence of bleeding disorders. During the screening process, patients
      will be asked about a history of coagulopathies such as hemophilia. In addition all patients
      will have their PT, PTT and platelets checked at baseline. Under sterile technique and after
      local anesthesia with 2% lidocaine, 5mls of bone marrow will be aspirated from the posterior
      iliac crest using a 16 gauge bone marrow aspiration needle attached to a 10 ml syringe. The
      sample will be placed on ice immediately and transported to the lab of Dr. George Beck. After
      the procedure, manual pressure will be applied to the aspiration site for a minimum of 5
      minutes to prevent bleeding. Patients blood pressure will be checked after the procedure and
      prior to their departure from the GCRC to ensure absence of hypotension due to lorazepam.

      E2b.2.1. Please see section E2c. below for experimental design on procurement of hBMCs from
      bone marrow aspirates and determination of osteoblast/adipocyte differentiation capacity from
      these hBMCs.

      E2b.3. BMD Evaluation: DXA measurements will be performed at the spine and dominant hip
      (contralateral hip in the presence of hardware in the dominant hip) using a GE Lunar Prodigy
      Instrument (GE medical Systems) at Grady Memorial Hospital. The DXA scanner is calibrated on
      a daily basis with the manufacturer's phantom according to manufacturer guidelines.
      Short-term root mean square coefficient of variation at our center is 1.1% at the lumbar
      spine and 1.5% at the total hip.

      E2b.4. Laboratory Assays: Bone formation markers (osteocalcin, procollagen type-I N-terminal
      propeptide [P1NP]) and bone resorption markers (β C-terminal telopeptide of type 1 collagen
      [β-CTX]) correlate strongly with rates of bone formation and resorption respectively and
      provide powerful data as they reflect the average bone turnover globally across all bone
      surfaces in the body. The disadvantage of these markers is that they reflect the final state
      at the time of sampling and not conditions at any other time point in the experiment.

      After an overnight fast, serum will be assayed from subjects between 8 and 9 am to control
      for diurnal variation. Blood samples will be collected and processed by nurses at the Grady
      GCRC core laboratory. Serum will be sent to the lab of Dr. George Beck and stored at -80◦C.
      The following analyses will be done at the end of the study in a single batch for each
      marker. Please see table 2 for details of each assay.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Number of Osteoblast and Adipocyte Colony Forming Units Cultured From Bone Marrow Stem Cells Harvested 6 Months After Treatment With Study Drug Compared to Baseline</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the effect of PIO (pioglitazone) on BMSC (bone marrow stem cell) lineage choice in vivo, a bone marrow aspiration was obtained from patients at baseline and after 6 months of treatment with PIO or placebo. The bone marrow was used for ex vivo CFU-OB (Colony forming units-Osteoblast) and CFU-AD assays using the same protocol described for the in vitro studies previously. We also analyzed the number of total colonies per patient at both baseline and final visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>βCTX (Carboxy Terminal Collagen Crosslinks), Osteocalcin, and Adiponectin.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Osteoblast</condition>
  <condition>Adipocytes</condition>
  <condition>Bone Density</condition>
  <condition>Osteocalcin</condition>
  <condition>Adiponectin</condition>
  <condition>Mesenchymal Stem Cells</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The other half will be randomized to placebo for 6 months. The placebo pills also start out with one &quot;15mg) pill qday and are increased to 2 tablets (&quot;30mg&quot;) qday after 4 weeks if no adverse effects are noted by study physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo pills also start out with one (&quot;15mg&quot;) pill qday and are increased to 2 tablets (&quot;30mg&quot;) qday after 4 weeks if no adverse effects are noted by study physician.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Subjects with T2DM who are:

          -  naïve to insulin and TZD therapy

          -  On diet and lifestyle therapy along with submaximal metformin therapy

          -  with HbA1c between 7% and 8.0%

          -  between the ages of 18 and 80 years

          -  both genders

        Exclusion Criteria:

          -  Contraindications to TZD therapy including congestive heart failure class III or IV,
             and/or macular edema

          -  history of osteoporosis (T score &lt; -2.5 on DXA scanning) or osteoporotic fragility
             fracture

          -  treatment with glucocorticoids within 1 year of study enrollment

          -  treatment with bisphosphonates,calcitriol, raloxifene, Calcitonin, estrogen

          -  vitamin D insufficiency, defined as 25(OH)D levels &lt;30 ng/mL or

          -  hyperparathyroidism

          -  liver disease (LFTS &gt; 3x upper limits of normal)

          -  Kidney disease Cr&gt;1.4 in females and Cr&gt;1.5 in males

          -  smokers (active or within a month from stopping)

          -  alcohol or drug abuse/dependence

          -  hypogonadism in males

          -  mental conditions rendering the subject unable to understand the scope of the study

          -  female subjects who are pregnant or breast feeding

          -  chronic obstructive pulmonary disease

          -  obstructive sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha B Khazai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Diabetes Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Beck GR Jr, Khazai NB, Bouloux GF, Camalier CE, Lin Y, Garneys LM, Siqueira J, Peng L, Pasquel F, Umpierrez D, Smiley D, Umpierrez GE. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res. 2013 Mar;161(3):145-55. doi: 10.1016/j.trsl.2012.08.006. Epub 2012 Sep 27.</citation>
    <PMID>23022285</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>May 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <last_update_submitted>March 2, 2016</last_update_submitted>
  <last_update_submitted_qc>March 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Natasha Khazai, M.D.</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>pioglitazone</keyword>
  <keyword>human bone marrow stem cells</keyword>
  <keyword>adipocytes</keyword>
  <keyword>osteoblasts</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>adiponectin</keyword>
  <keyword>leptin</keyword>
  <keyword>CTX</keyword>
  <keyword>P1NP</keyword>
  <keyword>Osteocalcin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3/09 to 4/11, diabetes clinic and grady hospital</recruitment_details>
      <pre_assignment_details>one participant failed to disclose that she was already on pioglitazone and was excluded</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qday for 4 weeks and if no adverse effects noted increased to 30mg qday for 5 more months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The other half will be randomized to placebo, starting out with 15mg qday for 4 weeks and if no adverse effects noted increased to 30mg qday for 5 more months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>half of the diabetic patients will be randomized to pioglitazone treatment for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The other half will be randomized to placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="10"/>
                    <measurement group_id="B2" value="60" spread="6"/>
                    <measurement group_id="B3" value="55" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Number of Osteoblast and Adipocyte Colony Forming Units Cultured From Bone Marrow Stem Cells Harvested 6 Months After Treatment With Study Drug Compared to Baseline</title>
        <description>To determine the effect of PIO (pioglitazone) on BMSC (bone marrow stem cell) lineage choice in vivo, a bone marrow aspiration was obtained from patients at baseline and after 6 months of treatment with PIO or placebo. The bone marrow was used for ex vivo CFU-OB (Colony forming units-Osteoblast) and CFU-AD assays using the same protocol described for the in vitro studies previously. We also analyzed the number of total colonies per patient at both baseline and final visit.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone-Osteoblast CFU (Colony Forming Units)</title>
            <description>Percent change in Osteoblast CFU numbers as stained with Alizarin red S at baseline and 6 months after treatment with study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-OSteoblast CFU</title>
            <description>Percent change in Osteoblast CFU numbers as stained with Alizarin at baseline and 6 months after treatment with study drug.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone-Adipocyte CFU</title>
            <description>Percent change in adipocyte CFU numbers as stained with Oil red O at baseline and 6 months after treatment with study drug.</description>
          </group>
          <group group_id="O4">
            <title>Placebo-Adipocyte CFU</title>
            <description>Percent change in adipocyte CFU numbers as stained with Oil red O, at baseline and 6 months after treatment with study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Number of Osteoblast and Adipocyte Colony Forming Units Cultured From Bone Marrow Stem Cells Harvested 6 Months After Treatment With Study Drug Compared to Baseline</title>
          <description>To determine the effect of PIO (pioglitazone) on BMSC (bone marrow stem cell) lineage choice in vivo, a bone marrow aspiration was obtained from patients at baseline and after 6 months of treatment with PIO or placebo. The bone marrow was used for ex vivo CFU-OB (Colony forming units-Osteoblast) and CFU-AD assays using the same protocol described for the in vitro studies previously. We also analyzed the number of total colonies per patient at both baseline and final visit.</description>
          <units>percent change from baseline to 6months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="12" spread="5"/>
                    <measurement group_id="O3" value="4" spread="4"/>
                    <measurement group_id="O4" value="-7" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>βCTX (Carboxy Terminal Collagen Crosslinks), Osteocalcin, and Adiponectin.</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone-Adiponectin</title>
            <description>serum adiponectin percent change 6 mo after study drug Rx compared to baseline.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Adiponectin</title>
            <description>serum adiponectin percent change 6 mo after placebo Rx compared to baseline.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone-CTX</title>
            <description>serum CTX percent change 6 mo after pioglitazone Rx compared to baseline.</description>
          </group>
          <group group_id="O4">
            <title>Placebo-CTX</title>
            <description>serum CTX percent change 6 mo after placebo Rx compared to baseline.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone-OSc</title>
            <description>serum Osteocalcin percent change 6 mo after pioglitazone Rx compared to baseline.</description>
          </group>
          <group group_id="O6">
            <title>Placebo - Osc</title>
            <description>serum Osteocalcin percent change 6 mo after placebo Rx compared to baseline.</description>
          </group>
        </group_list>
        <measure>
          <title>βCTX (Carboxy Terminal Collagen Crosslinks), Osteocalcin, and Adiponectin.</title>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="100.2"/>
                    <measurement group_id="O2" value="-0.6" spread="24.5"/>
                    <measurement group_id="O3" value="-9.2" spread="36.4"/>
                    <measurement group_id="O4" value="0.2" spread="25.9"/>
                    <measurement group_id="O5" value="3.6" spread="22.1"/>
                    <measurement group_id="O6" value="-5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone-Femoral Neck BMD</title>
            <description>half of the diabetic patients will be randomized to pioglitazone treatment for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-Femoral Neck BMD</title>
            <description>The other half will be randomized to placebo.</description>
          </group>
          <group group_id="O3">
            <title>Pioglitazone -Lumbar Spine BMD</title>
            <description>half of the diabetic patients will be randomized to pioglitazone treatment for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Lumbar Spine BMD</title>
            <description>The other half will be randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density</title>
          <units>percent change from baseline to 6 months</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="4.4"/>
                    <measurement group_id="O2" value="-2.6" spread="6.3"/>
                    <measurement group_id="O3" value="-1.1" spread="2.7"/>
                    <measurement group_id="O4" value="1.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>half of the diabetic patients will be randomized to pioglitazone treatment for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The other half will be randomized to placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. George Beck</name_or_title>
      <organization>Emory</organization>
      <phone>404-686-1000</phone>
      <email>gbeck@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

